Therapy Areas: Infectious Diseases
Terns Pharmaceuticals and Hansoh Pharma to develop and commercialise TRN-000632 for treatment of chronic myeloid leukemia in Greater China
28 July 2020 -

Biopharmaceutical company Terns Pharmaceuticals Inc and Hansoh Pharmaceutical Group Company Limited (Hansoh Pharma; 3692:HK), a biopharmaceutical company in Asia, on Tuesday declared a collaboration and license agreement in Greater China, for the development and commercialisation of TRN-000632, an investigational small molecule allosteric inhibitor of BCR-ABL for the treatment of chronic myeloid leukemia (CML).

According to the terms of the agreement, Terns will receive an upfront payment and will be eligible to receive development, regulatory and commercial milestones of up to USD68m,along with royalties from future product sales.

Hansoh will have exclusive rights to develop and commercialize TRN-000632 in Greater China, while Terns retains the right to develop and commercialize TRN-000632 in all other global markets.

Based in China and the US, Terns Pharmaceuticals is focused on the discovery and development of medicines for chronic liver disease and cancer. It is advancing a pipeline of drug candidates for the treatment of non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC) and cancer, across multiple modalities.

Hansoh Pharma has fully integrated research and development, manufacturing, and commercial capabilities, supporting leading positions in oncology, central nervous system (CNS) disorders, infectious diseases, gastrointestinal disorders, diabetes, and autoimmune diseases, among others in China.



Related Headlines